Intracavernous pharmacotherapy for erectile dysfunction

@article{Bella2007IntracavernousPF,
  title={Intracavernous pharmacotherapy for erectile dysfunction},
  author={A. Bella and G. Brock},
  journal={Endocrine},
  year={2007},
  volume={23},
  pages={149-155}
}
With the advent of phosphodiesterase type-5 inhibition as oral therapy, intracavernous injection of vasoactive agents has been relegated to second-line therapy for most patients with erectile dysfunction. However, the future of this category of agents remains bright as an ever-expanding number and combination of agents in use and under investigation will likely make intracavernous injection more appealing as greater efficacy, tolerability, and more rapid onset is attained. In this article… Expand
Phosphodiesterase 5 inhibitors and erectile dysfunction
TLDR
The use of PDE5 inhibitors within other indications beyond erectile dysfunction has become an important new aspect in the development of these drugs and will have a substantial influence on research and development within this unique class of drugs. Expand
The promise of inhibition of smooth muscle tone as a treatment for erectile dysfunction: where are we now?
TLDR
The various pathways involved in the maintenance of penile smooth muscle tone are outlined and the current potential benefit for the pharmacological inhibition of these targets for the treatment of ED is discussed. Expand
Emerging drugs for the treatment of erectile dysfunction
TLDR
The paper will examine the “second-generation” phosphodiesterase 5-inhibitors, soluble guanylate cyclases, rho-kinase inhibitors, and maxi-k channel activators that act peripherally, and the potential agents that target them. Expand
Erectile dysfunction in the aging man: current options for treatment
TLDR
Penile prosthesis implantation has the highest rate of success but is reserved as a final treatment option due to cost, invasiveness and irreversibility, and Gene therapy for erectile dysfunction is in the early stages of investigation. Expand
Update on the Treatment of Erectile Dysfunction
TLDR
The current treatment strategies, their efficacy, side effects, and pharmacodynamics are highlighted, as well as future considerations for the treatment of ED. Expand
Current Perspectives on Pharmacotherapy Treatments for Erectile Dysfunction
TLDR
As the world’s older population increases, it is estimated that the prevalence of ED will double from 152 million men in 1995 to 322 millionMen in 2025, indicating a dire need to reevaluate current ED therapeutic strategies. Expand
Optoelectronic method for increasing the sensibility of mass spectrometer in the case of the determination of papaverine
Papaverine is an opiate alkaloid used in the primary treatment of visceral spasms, cardiac and cerebral vasospasms, and occasionally for the treatment of erectile dysfunction [1]. Although found inExpand
channel therapeutics at the bedside
The family of potassium channel openers regroups drugs that share the property of activating adenosine triphosphate-sensitive potassium (KATP) channels, metabolic sensors responsible for adjustingExpand
Focused issue on KATP channels K ATP channel therapeutics at the bedside
The family of potassium channel openers regroups drugs that share the property of activating adenosine triphosphate-sensitive potassium (KATP) channels, metabolic sensors responsible for adjustingExpand
K(ATP) channel therapeutics at the bedside.
TLDR
K(ATP) channel openers have a unique therapeutic spectrum, ranging from applications in myopreservation and vasodilatation in patients with heart or vascular disease to potential clinical use as bronchodilators, bladder relaxants, islet cell protector, antiepileptics and promoters of hair growth. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 72 REFERENCES
New directions for erectile dysfunction therapies
TLDR
Some directions for future erectile dysfunction therapies can be identified, and strategies to prevent cavernosal degeneration and/or to restore cavernosal function will be one of the most exciting challenges for future research. Expand
Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction
  • H. Porst
  • Medicine
  • International Journal of Impotence Research
  • 2000
TLDR
A historical and current perspective on intracavernosal therapy is provided and the popular injectable therapeutic agents that are currently used for the treatment of ED are reviewed. Expand
Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction.
TLDR
The data suggest a possible role for SIN-1 in the treatment of erectile dysfunction, and possible advantages may be that erection is induced by a mechanism similar to that occurring physiologically, a decreased risk of inducing prolonged erections and low therapy costs. Expand
Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents
TLDR
Using the progressive method, by starting with the most available and inexpensive drugs, patients with erectile dysfunction can be given optimal treatment according to the severity of their disease, the success rate is high while costs are kept to a minimum. Expand
The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.
  • H. Porst
  • Medicine
  • The Journal of urology
  • 1996
TLDR
For self-injection therapy, P GE1 presently represents the most efficacious and safest drug and Ongoing trials with topical and especially intraurethral PGE1 are promising and may offer less invasive therapies in the near future. Expand
EFFICACY AND SAFETY OF INTRACAVERNOSAL ALPROSTADIL IN MEN WITH ERECTILE DYSFUNCTION
TLDR
The efficacy and safety of alprostadil formulated for intracavernosal treatment in men with erectile dysfunction of vasculogenic, neurogenic, psychogenic, and mixed causes were investigated in three separate multi-institutional, prospective studies. Expand
Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men
TLDR
If this form of therapy is chosen for aged men the triple combination therapy (PPR) yields a higher response rate than that obtained with prostaglandin alone, and a statistically significant association between the results obtained after the injection of PPR as compared to PE. Expand
Does prostaglandin E1 therapy modify the intracavernous musculature?
TLDR
Prostaglandin E1 does not seem to alter intracavernous structures and its quantification with computerized image analysis confirmed no histological difference was observed with classic staining. Expand
Vasoactive cocktails for erectile dysfunction: chemical stability of PGE1, papaverine and phentolamine.
TLDR
Papaverine and phentolamine are characterized by chemical stability when blended together or with PGE1, and a safe and proper use of these cocktails should take into account the variations of P GE1 concentration. Expand
An improved vasoactive drug combination for a pharmacological erection program.
TLDR
This vasoactive drug combination has been used in 116 patients for diagnostic testing and subsequent treatment and has been effective for diagnosis and treatment in the majority of patients with mild to moderate arteriogenic and/or venogenic and diabetic impotence. Expand
...
1
2
3
4
5
...